

2026 OU Cross-Campus Translational Biomedical Research Symposium



Moving Discovery to Healthcare: The **OU Cross-Campus Translational Biomedical Research Symposium (OU-CCTBRS)** will be held on September 25, 2026, bringing together leading researchers, clinicians and engineers from the University of Oklahoma’s Norman Campus, Tulsa Campus and Health Campus. This joint translational research event aims to strengthen collaboration and accelerate the discovery and translation of biomedical innovations. Hosted at the Samis Education Center at Oklahoma Children’s Hospital on the OU Health Campus, the OU-CCTBRS will showcase cutting-edge research and foster partnerships among the university’s academic and industry collaborators. As part of the symposium, participating departments will present competitive research awards recognizing outstanding translational presentations and posters. These awards are intended to highlight excellence in scientific communication among graduate students, postdoctoral fellows, clinical fellows, and early-career investigators. They also support the broader goals of promoting high-quality research dissemination, encouraging interdisciplinary collaboration, and advancing the university’s translational research mission.

ABSTRACT SUBMISSION GUIDELINES

Directions: Please carefully read these directions and then complete the submission form, providing the information requested.

1. There is no fee to submit an abstract to the 2026 OU Cross-Campus Translational Biomedical Research Symposium (OU-CCTBRS).
2. The submission deadline is **August 7, 2026 by 5 PM CST**. **The submission portal is now open (see #3).**
3. Your abstract should be submitted as a Microsoft Word document here:
https://qualtrics.ou.edu/jfe/form/SV_2ozYCG4OzUz5QsS.
 - a. More information regarding the formatting and content you will need for your abstract is provided within the ‘Preparing an Abstract’ section.
4. You have the option of being considered for the following two (2) awards: 1) The OU-CCTBRS Poster Award and 2) the OU-CCTBRS 3-Minute Translational Research Talk Award. *You will be prompted during the submission process to choose whether you wish to be included in either award competition.*

OU-CCTBRS POSTER AWARD

- i. The OU-CCTBRS will present up to 14 Poster Awards (up to \$300): for Undergraduate Students, Graduate Students/Medical Students, Post-doctoral Fellows/Clinical Fellows, Junior Faculty, and High School Students.
- ii. All individuals being considered for this Award will be judged on both their abstract and poster presentations.
- iii. Abstract submissions will be asked to indicate two of the following categories into which their abstract falls: a) Clinical Translational, b) Commercial Translational, c) Preclinical, d) Epidemiological, e) Behavioral, f) Bioengineering, and g) Biological. Please note that submitters are strongly encouraged to submit abstracts with a translational focus.

OU-CCTBRS 3-MINUTE TRANSLATIONAL RESEARCH TALK AWARD

- i. This competition is open to Graduate Students/Medical Students, Post-doctoral Fellows/Clinical Fellows, and Junior Faculty only. Due to time constraints, finalists will be selected in advance by the OU-CCTBRS Review Committee. Presenters will be announced by Monday, August 17, 2026.
- ii. Presenters will be selected based solely on their abstracts, while winners of this Award will be decided by judges based on their oral presentations. Award winners will receive a certificate and cash or travel award (up to \$300).

PREPARING AN ABSTRACT

Abstracts will be submitted via the above linked submission form. You will need to follow the formatting and content inclusion instruction present below:

- File format should be a Microsoft Word document.
- Abstract Title (max of 250 characters; avoid using special characters)
 - Should be in all caps, Calibri, 14-point font, left-aligned, single-spaced.
- Authors
 - List all authors as first name and last name, with the presenting author underlined.
 - Separate names with commas. **Do not** include academic credentials.
 - Should be Calibri, 12-point font, left-aligned, single-spaced.
 - Represent affiliations with superscripted numbers. Affiliation listings should be Calibri, 10-point font, left-aligned, single-spaced.

- A proofread and finalized **structured** abstract split into the following sections: Introduction, Methods, Results, and Translational Impact.
 - Abstracts have a 300-word limit.
 - You will be allowed to upload either one figure **or** one table, **not both**. Please ensure that they are easily readable. The 300-word limitation **will not be reduced** should you choose to add a figure or table. However, please do not use this upload to add further information beyond what is reviewed within the abstract as doing so may constitute grounds for abstract rejection.
 - Please do not use brand names within the abstract.
 - Do not indent paragraphs. Should be Calibri, 12-point font, justified alignment, single-spaced.
- Funding
 - List all funding sources separated by commas.
 - Should be Calibri, 12-point font, left-aligned, single-spaced.
- Footnotes
 - Should be Calibri, 10-point font, left-aligned, single-spaced

You will also be asked the following during the submission process:

- Whether OU-CCTBRS may publish your abstract. Please note, if you plan to present this work at another conference/meeting, some organizations have rules about duplicate presentations at meetings. You may need to check their policies.
- Your preferred presentation type: oral, poster, or no preference.
- Your current status: high school student, undergraduate student, graduate student/medical student, postdoctoral fellow/clinical fellow, junior faculty, or senior faculty.
- Whether you would like to be considered for the Awards outlined above.
- Whether you or any authors have a financial conflict of interest with the content of the presentation.

ACCEPTANCE OF THE ABSTRACT:

1. Abstracts will be compiled by the CRTEC office and forwarded to the Abstract Review Committee. This committee will review the abstracts and determine appropriateness for acceptance. Abstracts will be judged on the following categories:
 - a. **Introduction:** This should overview the need for and aims/novelty of the research.
 - b. **Methods:** Methods should be well described, robust with respect to the implicit/explicit research question(s), and appropriate for the study's aims.
 - c. **Results:** Results should be clear with respect to the analyses performed and directly address the aim(s)/research questions(s) of the study.

- d. **Translational Impact:** Potential for clinical or commercial application and the future direction(s) of your product, device, or intervention.
 - e. **Grammatical and Typographical Quality + Clarity:** Abstracts should be clear, concise, and grammatically correct as well as easy to understand and without typographical errors.
2. The Abstract Review Committee will make the final judgement as to the final status (i.e., accept or reject) of the abstract and, in isolated cases, may provide authors with the opportunity to correct critiques from reviewer feedback for resubmission to avoid rejection.
 3. The lead author will be notified by email concerning the status of the abstract. If accepted, the date/time of the presentation will be included.
 4. The presenting author must present the abstract.
 5. If you do not receive a notification by 5 PM CST, Monday, August 17, 2026, please contact Jill Rosewood-Evans at gillian-rosewoodevans@ou.edu.